Everything below concerns AOD-9604. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-08. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from C-terminal region of human growth hormone |
| Approximate molecular mass | About 1.8 kDa | Varies with sequence length and counterions |
| Confirmed receptor target | None established | No confirmed growth hormone receptor agonism |
| Reported in vitro activity | Lipolysis stimulation and lipogenesis inhibition | Observed mainly in adipocyte models; human relevance uncertain |
| Regulatory status | Not approved as a drug in major markets | May be treated differently across jurisdictions; not a recognized dietary ingredient in some countries |
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
The melamine food scare became a focal point against the warming relations between Taiwan's government and the Chinese government, and a major demonstration was held by the opposition Democratic Progressive Party on 25 October 2008 to voice dissatisfaction with Taiwan's increasingly closer ties with Beijing, notably related to the incident. Protesters fearful at reunification blamed the Kuomintang for the melamine scare, and criticised it for failing to stand up to China over the contamination. One citizen voiced concern that President Ma Ying-jeou's promise for closer ties with China would bring in more tainted products to Taiwan. The Minister of the Department of Health, Lin Fang-yue, was heavily criticised for raising the legally acceptable limit of melamine in food products from zero to 2.5 ppm. The public outcry subsequent to the move forced Lin to resign. His successor, Yeh Ching-chuan, announced a return to the original zero-tolerance policy to melamine.
in the bond orders within the rings, in the number of methyl groups attached to the ring (and, when present, on the prominent side chain at C17), in the functional groups attached to the rings and side chain, and in the configuration of groups attached to the rings and chain. For instance, sterols such as cholesterol and lanosterol have a hydroxyl group attached at position C-3, while testosterone and progesterone have a carbonyl (oxo substituent) at C-3. Among these compounds, only lanosterol has two methyl groups at C-4. Cholesterol which has a C-5 to C-6 double bond, differs from testosterone and progesterone which have a C-4 to C-5 double bond.
and Baltimore in August 2025, a spokesperson for Moore conceded that the project "had challenges that were insurmountable", but said that the Moore administration would continue working with the FRA on future transportation projects.
== Causes == Injuries to animals including humans can be caused by wounding, change in pressure, heat or cold, chemical substances, venoms and biotoxins. Such damage may result from attempted predation, territorial fights, falls, and abiotic factors. Human activities such as trawling can cause wound injury to a high proportion of seabed invertebrates; a study of a Nephrops lobster fishery found that all the discarded Ophiura ophiura brittlestars were injured, along with 57% of the Munida rugosa squat lobsters and 56% of the Astropecten irregularis starfish. Species with stronger shells such as scallops were less often injured. A study of beam trawling in contrast found survival rates over 75% for bottom-living invertebrates.
Imvescor was the parent company of the restaurant chains Scores, Pizza Delight, Mikes, Baton Rouge with a history that goes back to 1968. It was known as Pizza Delight Corporation until 2007, when the name was changed to Imvescor. As Pizza Delight Corporation, the company purchased Mikes in 2000 for $14.5 million, Quebec company Scores Rotisserie Barbecue and Ribs in 2005 for $32 million and Baton Rouge Restaurants. Headquartered in Moncton, the company was in charge of 259 restaurants across Canada (101 Pizza Delight, 91 Mikes, 39 Scores, and 28 Baton Rouge). Imvescor used to be a privately owned corporation that held the licence for the trademark and intellectual property of the four restaurants by PDM Royalties Income Fund. In 2009, the income fund and Imvescor combined their businesses into a new corporation called Imvescor Restaurant Group Inc. The four restaurant chains employed over 10,000 people. Total system sales in 2009 were $324.8 million. Imvescor is now owned by MTY Food Group, after being acquired in December 2017.
Sources: en.wikipedia.org
=== Safety aspects === Processing of nanocellulose does not cause significant exposure to fine particles during friction grinding or spray drying. No evidence of inflammatory effects or cytotoxicity on mouse or human macrophages can be observed after exposure to nanocellulose. The results of toxicity studies suggest that nanocellulose is not cytotoxic and does not cause any effects on inflammatory system in macrophages. In addition, nanocellulose is not acutely toxic to Vibrio fischeri in environmentally relevant concentrations. Despite intensified research on oral food or pharmaceutical formulations containing nanocelluloses they are not generally recognized as safe. Nanocelluloses were demonstrated to exhibit limited toxicity and oxidative stress in in vitro intestinal epithelium or animal models.
Health can play a central role in how people live their lives, reflecting the overall condition in which an organism functions properly, both physically and mentally. Good physical health is associated with high energy and the ability to perform everyday activities. Physical illnesses and disabilities can negatively impact well-being by causing pain, limiting mobility, and reducing the capacity to engage in enjoyable or necessary activities. Good mental health is a state of internal equilibrium in which mental capacities function as they should. Mental disorders are associated with some form of psychological impairment: they typically disrupt the equilibrium by causing distress and may limit the activities a person can engage in. Discrimination can amplify the negative effects of socially stigmatized illnesses and disabilities. Despite its general impact, health does not fully determine happiness, and some individuals affected by severe illnesses and disabilities report high levels of subjective well-being. The availability of healthcare services can mitigate negative effects by providing treatments to restore health or manage and alleviate symptoms. Similarly, adopting a healthy lifestyle, like regular physical activity and a balanced diet, is associated with long-term benefits to well-being.
=== Legal issues === On August 11, 2013, Riff Raff was arrested in Greensboro, North Carolina after police found an open container of alcohol, marijuana, another unspecified illegal substance and drug paraphernalia in his vehicle. Riff Raff was booked into jail along with the two passengers in his vehicle, and was released without bail later that night. On May 31, 2018, Riff Raff was accused of drugging and raping a woman after a 2013 show in Melbourne. All venues on his Australian and New Zealand tour subsequently canceled his scheduled concerts. Afterward, a second woman, aged 17 at the time, alleged that in Milwaukee, Riff Raff invited her on his tour bus; according to the accuser, he proceeded to touch her repeatedly while making suggestive comments. On January 22, 2020, Riff Raff settled a lawsuit related to a sexual assault claim made against him, from a 2014 incident at a Nevada brothel.
== Semantics of changing care: why "flexible" is replacing "intensive" therapy == Over the last two decades, the evidence that better glycemic control (i.e., keeping blood glucose and HbA1c levels as close to normal as possible) reduces the rates of many complications of diabetes has become overwhelming. As a result, diabetes specialists have expended increasing effort to help most people with diabetes achieve blood glucose levels as close to normal as achievable. It takes about the same amount of effort to achieve good glycemic control with a traditional two or three injection regimen as it does with flexible therapy: frequent glucose monitoring, attention to timing and amounts of meals. Many diabetes specialists no longer think of flexible insulin therapy as "intensive" or "special" treatment for a select group of patients but simply as standard care for most patients with type 1 diabetes.
== History of discovery == Profilin was first described by Lars Carlsson in the lab of Uno Lindberg and co-workers in the early 1970s as the first actin monomer binding protein. It followed the realization that not only muscle, but also non-muscle cells, contained high concentrations of actin, albeit in part in an unpolymerized form. Profilin was then believed to sequester actin monomers (keep them in a pro-filamentous form), and release them upon a signal to make them accessible for fast actin polymer growth.
Sources: en.wikipedia.org
=== Brand names === As of June 2017, Minoxidil is sold under many brand names worldwide, including but not limited to: Alomax, Alopek, Alopexy, Alorexyl, Alostil, Aloxid, Aloxidil, Anagen, Apo-Gain, Axelan, Belohair, Boots Hair Loss Treatment, Botafex, Capillus, Carexidil, Coverit, Da Fei Xin, Dilaine, Dinaxcinco, Dinaxil, Ebersedin, Eminox, Folcare, Follixil, Guayaten, Hair Grow, Hair-Treat, Hairgain, Hairgaine, Hairgrow, Hairway, Headway, Inoxi, Ivix, Keranique, Lacovin, Locemix, Loniten, Lonnoten, Lonolox, Lonoten, Loxon, M E Medic, Maev-Medic, Mandi, Manoxidil, Mantai, Men's Rogaine, Minodil, Minodril, Minostyl, Minovital, Minox, Minoxi, Minoxidil, Minoxidilum, Minoximen, Minoxiten, Minscalp, Mintop, Modil, Morr, Moxidil, Neo-Pruristam, Neocapil, Neoxidil, Nherea, Nioxin, Noxidil, Oxofenil, Pilfud, Pilogro, Pilomin, Piloxidil, Re-Stim, Re-Stim+, Recrea, Regain, Regaine, Regaxidil, Regro, Regroe, Regrou, Regrowth, Relive, Renobell Locion, Reten, Rexidil, Rogaine, Rogan, Scalpmed, Si Bi Shen, Splendora, Superminox, Trefostil, Tricolocion, Tricoplus, Tricovivax, Tricoxane, Trugain, Tugain, Unipexil, Vaxdil, Vius, Women's Regaine, Xenogrow, Xtreme Boost, Xtreme Boost+, Xue Rui, Ylox, and Zeldilon. It is also sold as a combination medication with amifampridine under the brand names Gainehair and Hair 4 U; and as a combination with tretinoin and clobetasol under the brand name Sistema GB.
=== Hebrew === The longest Hebrew word is the 19-letter-long (including vowels) וכשלאנציקלופדיותינו (u'chshelentsiklopediotenu), which means "And when to our encyclopedias..." The Hebrew word אנציקלופדיה (encyclopedia) is of a European origin. The longest word in Hebrew that doesn't originate from another language is וכשלהתמרמרויותינו, (u'chshelehitmarmeruyotenu) which crudely means "And when, to our resentments/ grievances" The 11-letter-long (including vowels) וְהָאֲחַשְׁדַּרְפְּנִים (veha'aḥashdarpením) (Esther 9:3) is the longest word to appear in the Hebrew Bible. – Its meaning is "And the satraps". It also does not originate from Hebrew. Other very long Hebrew words include:
Some genetically modified plants are purely ornamental. They are modified for flower color, fragrance, flower shape and plant architecture. The first genetically modified ornamentals commercialized altered color. Carnations were released in 1997, with the most popular genetically modified organism, a blue rose (actually lavender or mauve) created in 2004. The roses are sold in Japan, the United States, and Canada. Other genetically modified ornamentals include Chrysanthemum and Petunia. As well as increasing aesthetic value there are plans to develop ornamentals that use less water or are resistant to the cold, which would allow them to be grown outside their natural environments. It has been proposed to genetically modify some plant species threatened by extinction to be resistant to invasive plants and diseases, such as the emerald ash borer in North American and the fungal disease, Ceratocystis platani, in European plane trees. The papaya ringspot virus devastated papaya trees in Hawaii in the twentieth century until transgenic papaya plants were given pathogen-derived resistance. However, genetic modification for conservation in plants remains mainly speculative. A unique concern is that a transgenic species may no longer bear enough resemblance to the original species to truly claim that the original species is being conserved. Instead, the transgenic species may be genetically different enough to be considered a new species, thus diminishing the conservation worth of genetic modification.
The instrumentation needed to perform capillary electrophoresis is relatively simple. A basic schematic of a capillary electrophoresis system is shown in figure 1. The system's main components are a sample vial, source and destination vials, a capillary, electrodes, a high-voltage power supply, a detector, and a data output and handling device. The source vial, destination vial and capillary are filled with an electrolyte such as an aqueous buffer solution. To introduce the sample, the capillary inlet is placed into a vial containing the sample. Sample is introduced into the capillary via capillary action, pressure, siphoning, or electrokinetically, and the capillary is then returned to the source vial. The migration of the analytes is initiated by an electric field that is applied between the source and destination vials and is supplied to the electrodes by the high-voltage power supply. In the most common mode of CE, all ions, positive or negative, are pulled through the capillary in the same direction by electroosmotic flow. The analytes separate as they migrate due to their electrophoretic mobility, and are detected near the outlet end of the capillary. The output of the detector is sent to a data output and handling device such as an integrator or computer. The data is then displayed as an electropherogram, which reports detector response as a function of time. Separated chemical compounds appear as peaks with different migration times in an electropherogram. The technique is often attributed to James W.
=== Congressional testimony === In June 2025, Powell testified before Congress regarding the renovation project. Under questioning, he denied that the current plans included luxury features such as VIP dining rooms, special elevators, or new marble installations, stating that existing marble was being reused where possible and that certain earlier proposals had been eliminated as plans evolved. Following the hearing, the Federal Reserve published a “Frequently Asked Questions” document and released additional materials, including photographs and annotated planning documents, reaffirming Powell’s testimony and explaining changes to the project over time. Critics argued that Powell’s testimony conflicted with earlier planning documents, raising questions about whether his statements were misleading. Powell has maintained that his answers accurately reflected the project as it existed at the time of his testimony. In July 2025, U.S. Representative Anna Paulina Luna of Florida made a criminal referral to the Justice Department over Powell's testimony to the Senate Banking Committee the previous month.
Sources: en.wikipedia.org
AOD9604 is a synthetic peptide based on a C-terminal segment of human growth hormone. It is manufactured by chemical peptide synthesis rather than extracted from human tissue. The sequence is often described as hGH fragment 176–191 or a close variant.
It is not approved as a prescription drug in the United States or the European Union for any indication. Regulatory status can differ by country, and it is often sold as a research chemical or in unapproved products. Such products are not equivalent to an approved medicine.
In the studies reported so far, AOD9604 does not appear to act through the growth hormone receptor and has not shown the typical IGF-1 increase caused by full-length hGH. Human data are limited, so this remains an area of uncertainty. It should not be assumed to have the same effects as hGH.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.